Zhengye Biotechnology Holding Limited (ZYBT)
NASDAQ: ZYBT · Real-Time Price · USD
2.660
+0.100 (3.91%)
At close: Oct 17, 2025, 4:00 PM EDT
2.610
-0.050 (-1.88%)
After-hours: Oct 17, 2025, 4:37 PM EDT
ZYBT Revenue
In the year 2024, Zhengye Biotechnology Holding had annual revenue of 186.36M CNY, down -11.95%. Zhengye Biotechnology Holding had revenue of 91.41M in the half year ending December 31, 2024, a decrease of -33.24%.
Revenue (ttm)
186.36M CNY
Revenue Growth
-11.95%
P/S Ratio
4.76
Revenue / Employee
672,765 CNY
Employees
277
Market Cap
126.06M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 186.36M | -25.30M | -11.95% |
Dec 31, 2023 | 211.65M | -48.62M | -18.68% |
Dec 31, 2022 | 260.27M | 46.20M | 21.58% |
Dec 31, 2021 | 214.07M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZYBT News
- 3 months ago - Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results - PRNewsWire
- 5 months ago - Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - GlobeNewsWire
- 9 months ago - Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 10 months ago - U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline - Seeking Alpha
- 10 months ago - Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering - GlobeNewsWire
- 10 months ago - Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering - GlobeNewsWire
- 1 year ago - Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO - Seeking Alpha
- 1 year ago - Chinese animal health company Zhengye Biotechnology Holding files for a $20 million US IPO - Renaissance Capital